Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study

Gene Therapy

Volumn 5, Issue 4, 1998, Pages 481-490

  Sun, Y ^a,b   Jurgovsky, K ^a,c   Moller P ^a,b   Alijagic, S ^a   Dorbic, T ^b,c   Georgieva, J ^a   Wittig, B ^b,c   Schadendorf, D ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Ctr fur Somatische Gentherapie eV   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cytokine gene transfer; DTH reactivity; IL 12 secretion

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12;

ADULT; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SEPARATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; EXPRESSION VECTOR; FEMALE; FEVER; GENE INSERTION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MELANOMA; MELANOMA CELL; MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE; TERMINAL DISEASE; TUMOR BIOPSY; VACCINATION;

ANIMALIA; EUKARYOTA;

EID: 0031895957     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300619     Document Type: Article

References (40)

1. Ho VC, Sober AJ. Therapy of cutaneous melanoma: an update. J Am Acad Dermatol 1990; 22: 159-176.
2. Ahmann DL et al. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989; 63: 224-227.
3. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-7.
4. Boon T et al. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. JB Lippincott Co: Philadelphia, 1994, pp 53-69.
5. Vieweg J, Gilboa E. Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Treat Rev 1995; 13: 193-201.
6. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 3: 399-415.
7. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
8. Brunda MJ et al. Anti-tumor and antimetastatic activity of interleukm 12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
9. Brunda MJ, Gately MK. Interleukin-12: potential role in cancer therapy. In: deVita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. JB Lippincott Co: Philadelphia, 1995, pp 3-18.
10. Nishimura T et al. Application of interleukin 12 to anti-tumor cytokine and gene therapy. Cancer Chemother Pharmacol 1996; 38 (Suppl.) S27-S34.
11. Tan J et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996; 56: 3399-3403.
12. Tahara H et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-189.
13. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
14. Fujiwara H, Hamaoka T. Anti-tumor and antimetastatic effects of interleukin 12. Cancer Chemother Pharmacol 1996; 38 (Suppl.): S22-S26.
15. Brunda MJ et al. Anti-tumor activity of interleukin 12 in preclinical models Cancer Chemother Pharmacol 1996; 38 (Suppl.): S16-521.
16. Windhagen A et al. IL-12 induces human T cells secreting IL-10 and IFN-γ J Immunol 1996; 157: 1127-1131.
17. Trinchieri G. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13: 251-276.
18. Hendrzak JA, Brunda MJ. Interleukin 12: biologic activity, therapeutic utility, and role in disease. Lab Invest 1995; 72: 619-637.
19. Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995; 71: 655-659.
20. Dalgleish A. The case for therapeutic vaccines. Melanoma Res 1996; 6: 5-10.
21. Parmiani G, Colombo MP. Somatic gene therapy of human melanoma: prelinical studies and early clinical trials. Melanoma Res 1995; 5: 295-301.
22. Tahara H et al. Clinical protocol: IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 1995; 6: 1607-1624.
23. Atkins MB et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409-417.
24. Arienti F et al. Limited anti-tumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allo-geneic melanoma cells. Hum Gene Ther 1996; 7: 1955-1963.
25. Veelken H et al. A phase I clinical study of autologous tumor cells plus interleukin-2 gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 1997; 70: 269-277.
26. Claessen AME et al. Reversal of mucosal tolerance by sucutaneous administration of interleukin-12 at the site of attempted sensitization. Immunology 1996; 88: 363-367.
27. Germann T et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 1995; 92: 4823-4827.
28. Schadendorf D, Czarnetzki BM, Wittig B. Interleukin-7, interleukin-12 and GM-CSF gene transfer in patients with metastatic melanoma. J Mol Med 1995; 73: 473-477.
29. Möller P et al. Vaccination with IL-7-gene modified autologous tumor cells enhances tumor-specific T-cell precursor frequency and modulates cytokine secretion in patients with advanced malignant melanoma - a clinical phase I study. Br J Cancer 1998 (in press).
30. Schadendorf D et al. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 1995; 87: 366-371.
31. Gudat F et al. The tumor-associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchow Arch 1996; 429: 77-81.
32. Kocher T et al. Identification and intracellular localization of MAGE-3 gene product. Cancer Res 1995; 55: 2236-2239.
33. Chen YT et al. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93: 5915-5919.
34. Chen YT et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92: 8125-8129.
35. Thompson TM et al. Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol 1985; 85: 169-174.
36. Schadendorf D et al. Metastatic potential of human melanoma cells in nude mice - characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer 1996; 74: 194-199.
37. Blumberg RS et al. Effects of human immunodeficiency virus on cellular immune response to Epstein-Barr virus in homosexual men: characterization of cytotoxic response and lymphokine production. J Infect Dis 1987; 155: 877-890.
38. Coulie P et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992; 50: 289-297.
39. Decker T, Lohmann-Matthes ML. A quick and simple method for quantification of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Meth 1988; 15: 61-69.
40. Taswell C. Limiting dilution assay for the determination of immunocompetent cell frequencies: I. data analysis. J Immunol 1981; 126: 1614-1619.